Personal information

No personal information available

Activities

Collapse all

Employment (4)

Sheffield Teaching Hospitals NHS Foundation Trust: Sheffield, Sheffield, GB

2020-08 to present | Academic Clinical Fellow in Medical Oncology
Employment
Source: Self-asserted source
Gustavo Arias-Pinilla

Birmingham Heartlands Hospital: Birmingham, West Midlands, GB

2019-10 to 2020-08 | Junior Specialist Doctor Medicine
Employment
Source: Self-asserted source
Gustavo Arias-Pinilla

Queen Elizabeth Hospital Birmingham: Birmingham, Birmingham, GB

2018-04 to 2019-10 | Junior Specialist Doctor Oncology/Haematology
Employment
Source: Self-asserted source
Gustavo Arias-Pinilla

Kingston University: Kingston-Upon-Thames, London, GB

2017 | Postdoctoral Research Fellow in Cancer Biology
Employment
Source: Self-asserted source
Gustavo Arias-Pinilla

Education and qualifications (4)

The University of Sheffield: Sheffield, Sheffield, GB

2020 to present | PgCert Clinical Research
Education
Source: Self-asserted source
Gustavo Arias-Pinilla

Kingston University: Kingston-Upon-Thames, London, GB

2017 | PhD
Qualification
Source: Self-asserted source
Gustavo Arias-Pinilla

Kingston University: Kingston-Upon-Thames, London, GB

2012 | MSc Cancer Biology
Qualification
Source: Self-asserted source
Gustavo Arias-Pinilla

Fundación Universitaria Juan N Corpas: Bogota, CO

2009 | MBBS
Qualification
Source: Self-asserted source
Gustavo Arias-Pinilla

Professional activities (3)

European Association for Cancer Research: ., GB

Membership
Source: Self-asserted source
Gustavo Arias-Pinilla

American Association for Cancer Research: PA, PA, US

Membership
Source: Self-asserted source
Gustavo Arias-Pinilla

Kingston University: Kingston-Upon-Thames, London, GB

2019-03-01 to 2021-03-01 | Visiting Researcher (School of Life Sciences, Pharmacy and Chemistry)
Invited position
Source: Self-asserted source
Gustavo Arias-Pinilla

Works (7)

The effects of anticancer therapies on bone metastases in breast cancer

Bone Cancer
2022 | Book chapter
DOI: 10.1016/b978-0-12-821666-8.00069-4
Part of ISBN: 9780128216668
Source: Self-asserted source
Gustavo Arias-Pinilla

Management of bone metastasis and cancer treatment-induced bone loss during the COVID-19 pandemic: An international perspective and recommendations

Journal of Bone Oncology
2021-08 | Journal article
DOI: 10.1016/j.jbo.2021.100375
Part of ISSN: 2212-1374
Source: Self-asserted source
Gustavo Arias-Pinilla

Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities

Cancers
2021-04-08 | Journal article
DOI: 10.3390/cancers13081781
Contributors: Gustavo A. Arias-Pinilla; Helmout Modjtahedi
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin α3 in human pancreatic cancer.

Scientific reports
2020-01 | Journal article
DOI: 10.1038/s41598-019-57287-w
PMID: 31953437
PMC: PMC6969035
Contributors: Arias-Pinilla GA; Dalgleish AG; Mudan S; Bagwan I; Walker AJ; Modjtahedi H
Source: Self-asserted source
Gustavo Arias-Pinilla via Europe PubMed Central

Abstract 5758: Generation and characterization of novel monoclonal antibodies against overexpressed CD109 on pancreatic cancer cells for use in diagnosis and therapy

2018 American Association for Cancer Research
2018-07-01 | Conference poster
Source: Self-asserted source
Gustavo Arias-Pinilla

PO-043 Development of two novel monoclonal antibodies against overexpressed antigens on pancreatic cancer cells for use in diagnosis and therapy

25th Biennial Congress of the European Association for Cancer Research
2018-06 | Conference poster
Source: Self-asserted source
Gustavo Arias-Pinilla

Development of novel monoclonal antibodies against CD109 overexpressed in human pancreatic cancer.

Oncotarget
2018-04 | Journal article
DOI: 10.18632/oncotarget.25017
PMID: 29731998
PMC: PMC5929441
Contributors: Arias-Pinilla GA; Dalgleish AG; Mudan S; Bagwan I; Walker AJ; Modjtahedi H
Source: Self-asserted source
Gustavo Arias-Pinilla via Europe PubMed Central
How many people are using ORCID?